Biologics:
Biologics are a type of treatment that target the immune system to reduce inflammation and slow down the rapid growth of skin cells associated with psoriasis. This sub-segment includes drugs like adalimumab, etanercept, and ustekinumab, which are widely used for moderate to severe psoriasis. Biologics are often preferred by patients who have not responded well to other treatments or have severe psoriasis that affects a large area of their body.
Topical Treatments:
Topical treatments are applied directly to the skin and are often used for mild to moderate cases of psoriasis. This sub-segment includes products such as corticosteroids, vitamin D analogs, and retinoids. These treatments help to reduce inflammation, itchiness, and scaling associated with psoriasis. They are often the first line of treatment for individuals with psoriasis affecting a small area of their body.
Get more details on this report -
Competitive Landscape:
The competitive landscape of the psoriasis treatment market is characterized by the presence of several key players who are focused on the development of innovative and effective treatment options for patients. Some of the prominent companies in the market include AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, and Pfizer Inc. These companies are actively engaged in research and development activities to introduce novel therapies for the management of psoriasis.
Furthermore, collaborations, partnerships, and strategic acquisitions are common strategies adopted by these market players to expand their product offerings and strengthen their position in the market. For instance, Novartis AG acquired the rights to tildrakizumab, a biologic treatment for psoriasis, from Almirall, S.A. in order to enhance its psoriasis treatment portfolio. Such strategic initiatives contribute to the overall growth and competitiveness of the psoriasis treatment market.